Oruka Therapeutics files $500 million at-the-market stock offering with TD CowenAug 28FinancingOruka Therapeutics, Inc.
Oruka Therapeutics registers Phase 2 study of ORKA-002 in hidradenitis suppurativaAug 24Trial updateORKA-002Oruka Therapeutics, Inc.
Oruka reports Q2 2026 results, advances ORKA-001 and ORKA-002 programsAug 10Quarterly updateORKA-001ORKA-002
Sign inSign in